Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region' by Rinaudo-Gaujous et al

Ann Rheum Dis. 2015 Aug;74(8):e41. doi: 10.1136/annrheumdis-2015-207529. Epub 2015 Apr 8.

Authors

K A van Schie¹, M H Hart¹, E R de Groot¹, S Kruithof¹, L A Aarden¹, G J Wolbink², T Rispens¹

Affiliations

¹ Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands.

PMID: 25854585
DOI: 10.1136/annrheumdis-2015-207529

No abstract available

Keywords: Anti-TNF; Inflammation; Treatment.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / immunology*
Antibodies, Neutralizing / immunology*
Antirheumatic Agents / immunology*
Binding Sites, Antibody / immunology*
Humans

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antirheumatic Agents